Biopharmaceutical firm Alumis's Q3 net loss widens

Reuters

Nov 14, 2025

Biopharmaceutical firm Alumis's Q3 net loss widens

Overview

Alumis Q3 net loss widens to $110.8 mln from $93.1 mln a year ago
Company reports $2.1 mln collaboration revenue for Q3 2025
Operating expenses rise due to increased R&D and merger costs

Outlook

Alumis expects topline Phase 3 ONWARD data in early Q1 2026
Company anticipates Phase 2b LUMUS data in Q3 2026
Alumis plans Phase 2 trial for A-005 in H1 2026

Result Drivers

INCREASED R&D EXPENSES - Alumis attributes rise in R&D expenses to increased contract research and clinical trial costs, including for envudeucitinib
MERGER COSTS - Alumis cites merger with ACELYRIN as contributing to increased general and administrative expenses

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$110.75 mln
Q3 Income From Operations		-$115.29 mln
Q3 Operating Expenses		$117.36 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Alumis Inc is $18.00, about 70.9% above its November 12 closing price of $5.24

Press Release: ID:nGNX7tkZXF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583551277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583551277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583551277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583551277","market":"us","top_or_hot":-1,"title":"Biopharmaceutical firm Alumis's Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharmaceutical firm Alumis's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Alumis Q3 net loss widens to $110.8 mln from $93.1 mln a year ago</p></li><li><p>Company reports $2.1 mln collaboration revenue for Q3 2025</p></li><li><p>Operating expenses rise due to increased R&amp;D and merger costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Alumis expects topline Phase 3 ONWARD data in early Q1 2026</p></li><li><p>Company anticipates Phase 2b LUMUS data in Q3 2026</p></li><li><p>Alumis plans Phase 2 trial for A-005 in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Alumis attributes rise in R&amp;D expenses to increased contract research and clinical trial costs, including for envudeucitinib</p></li><li><p>MERGER COSTS - Alumis cites merger with ACELYRIN as contributing to increased general and administrative expenses</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$110.75 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations </p></td><td></td><td><p>-$115.29 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$117.36 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Alumis Inc is $18.00, about 70.9% above its November 12 closing price of $5.24</p></li></ul><p>Press Release: <span>ID:nGNX7tkZXF</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharmaceutical firm Alumis's Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharmaceutical firm Alumis's Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharmaceutical firm Alumis's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Alumis Q3 net loss widens to $110.8 mln from $93.1 mln a year ago</p></li><li><p>Company reports $2.1 mln collaboration revenue for Q3 2025</p></li><li><p>Operating expenses rise due to increased R&amp;D and merger costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Alumis expects topline Phase 3 ONWARD data in early Q1 2026</p></li><li><p>Company anticipates Phase 2b LUMUS data in Q3 2026</p></li><li><p>Alumis plans Phase 2 trial for A-005 in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Alumis attributes rise in R&amp;D expenses to increased contract research and clinical trial costs, including for envudeucitinib</p></li><li><p>MERGER COSTS - Alumis cites merger with ACELYRIN as contributing to increased general and administrative expenses</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$110.75 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations </p></td><td></td><td><p>-$115.29 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$117.36 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Alumis Inc is $18.00, about 70.9% above its November 12 closing price of $5.24</p></li></ul><p>Press Release: <span>ID:nGNX7tkZXF</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP1A2:1","article_id":"2583551277","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583551277","pubTimestamp":1763069789,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharmaceutical firm Alumis's Q3 net loss widensOverviewAlumis Q3 net loss widens to $110.8 mln from $93.1 mln a year agoCompany reports $2.1 mln collaboration revenue for Q3 2025Operating expenses ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ALMS":"Alumis Inc."},"translate_title":"生物制药公司Alumis第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":0.9},"content_text":"Biopharmaceutical firm Alumis's Q3 net loss widensOverviewAlumis Q3 net loss widens to $110.8 mln from $93.1 mln a year agoCompany reports $2.1 mln collaboration revenue for Q3 2025Operating expenses rise due to increased R&D and merger costsOutlookAlumis expects topline Phase 3 ONWARD data in early Q1 2026Company anticipates Phase 2b LUMUS data in Q3 2026Alumis plans Phase 2 trial for A-005 in H1 2026Result DriversINCREASED R&D EXPENSES - Alumis attributes rise in R&D expenses to increased contract research and clinical trial costs, including for envudeucitinibMERGER COSTS - Alumis cites merger with ACELYRIN as contributing to increased general and administrative expensesKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$110.75 mlnQ3 Income From Operations -$115.29 mlnQ3 Operating Expenses$117.36 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Alumis Inc is $18.00, about 70.9% above its November 12 closing price of $5.24Press Release: ID:nGNX7tkZXFFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}